Literature DB >> 26432184

Recurrent Clostridium difficile infection in intensive care unit patients.

Natalia M Jasiak1, Cesar Alaniz1, Krishna Rao2, Katherine Veltman3, Jerod L Nagel4.   

Abstract

BACKGROUND: The purpose of this study was to assess the 12-week cumulative incidence of recurrent Clostridium difficile infection (rCDI) and identify risk factors for rCDI in patients that acquired index C difficile infection (CDI) while in the intensive care unit (ICU).
METHODS: This retrospective single-center cohort study reviewed adult patients from 6 different ICUs who developed a CDI between February 2010 and September 2013.
RESULTS: Out of 162 included ICU patients, 34 experienced rCDI. Risk of rCDI was higher in the ICU versus non-ICU group (21% vs 17%, P = .03). The incidence of rCDI was highest in the surgical intensive care unit (SICU) at 43.8%. A multivariable logistic regression model was constructed and identified 5 significant risk factors for rCDI: previous CDI (odds ratio [OR], 8.03; 95% confidence interval [CI], 1.90-34.02; P = .005), log10 ICU length of stay in days (OR, 3.67; 95% CI, 1.13-11.85; P = .03), acquisition of CDI in the medical intensive care unit (MICU) (OR, 5.35; 95% CI, 1.60-17.85; P = .006) or SICU (OR, 15.30; 95% CI, 4.09-57.23; P < .001), and chronic obstructive pulmonary disease (COPD) (OR, 3.55; 95% CI, 1.41-8.94; P = .007).
CONCLUSION: ICU adults had a significantly higher 12-week incidence of rCDI than non-ICU patients. Risk factors for rCDI after acquisition of infection in an ICU include MICU and SICU patients, previous CDI, COPD, and length of stay.
Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Colitis; Health care–associated infection; Intensive care unit; Recurrence

Mesh:

Year:  2015        PMID: 26432184     DOI: 10.1016/j.ajic.2015.08.013

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  4 in total

1.  Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.

Authors:  Natasa Popovic; Milos Korac; Zorica Nesic; Branko Milosevic; Aleksandar Urosevic; Djordje Jevtovic; Nikola Mitrovic; Aleksandar Markovic; Jelena Jordovic; Natasa Katanic; Aleksandra Barac; Ivana Milosevic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-03       Impact factor: 3.267

Review 2.  Clostridium difficile Infection in Special High-Risk Populations.

Authors:  Alberto Cózar-Llistó; Antonio Ramos-Martinez; Javier Cobo
Journal:  Infect Dis Ther       Date:  2016-08-11

3.  Risk Factors Associated With Recurrent Clostridium difficile Infection.

Authors:  Nikhita Dharbhamulla; Ahmed Abdelhady; Mona Domadia; Sanket Patel; John Gaughan; Satyajeet Roy
Journal:  J Clin Med Res       Date:  2018-12-03

4.  Impacts of Corticosteroid Therapy at Acute Stage of Hospital-Onset Clostridioides difficile Infections.

Authors:  Ching-Chi Lee; Jen-Chieh Lee; Chun-Wei Chiu; Pei-Jane Tsai; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Infect Drug Resist       Date:  2022-09-10       Impact factor: 4.177

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.